Education
About Us
Working with TipRanks
Follow Us
Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE
RCE Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.29 - AU$0.70
Previous CloseN/A
Volume21.12K
Average Volume (3M)273.44K
Market Cap
AU$67.24M
Enterprise ValueAU$118.79M
Total Cash (Recent Filing)AU$35.28K
Total Debt (Recent Filing)AU$456.00K
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding231,871,610
10 Day Avg. Volume187,201
30 Day Avg. Volume273,445
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Recce Pharmaceuticals Ltd. News
PremiumCompany Announcements
Recce Pharmaceuticals Updates Investors on Clinical Progress and Funding
PremiumCompany Announcements
Recce Pharmaceuticals Opens Entitlement Offer to Raise $10.8 Million
PremiumCompany Announcements
Recce Pharmaceuticals Expands Phase II Trial for Diabetic Foot InfectionsPremiumCompany Announcements
Recce Pharmaceuticals Raises A$5 Million Through Share Placement
PremiumCompany Announcements
Recce Pharmaceuticals Secures Funding for Advanced Clinical TrialsPremiumCompany Announcements
Recce Pharmaceuticals Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Recce Pharmaceuticals Announces Investor Webinar and Funding Update---
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.29 and its highest was AU$0.69 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is AU$67.24M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 29, 2025 which is in 125 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2025. The company reported -AU$0.033 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.033.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 231,871,610 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.033 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
---
Recce Pharmaceuticals Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RCE Sentiment 66%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.13%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
---
Technical Analysis
Biotron Limited
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
PYC Therapeutics Limited
―
Arovella Therapeutics Limited
―
---